Supercharged immune cells take on advanced cancers in tiny trial
NCT ID NCT01697527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new approach for people with advanced cancers that have not responded to other treatments. Doctors take a patient's own white blood cells, genetically modify them to recognize a protein called NY-ESO-1 found on some cancer cells, and infuse them back after mild chemotherapy. A special vaccine is also given to boost the immune response. Only 6 participants are enrolled, making this a very early look at whether the strategy is safe and shows promise.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified immune cells (NY-ESO-1 TCR-engineered T cells) plus a vaccine (NY-ESO-1 pulsed dendritic cells) and interleukin-2
- What this could lead to
- If successful, this approach could point toward a new treatment option for advanced cancers that express the NY-ESO-1 protein.
- What could go wrong
- This is a very small, early-phase trial with only 6 participants, so results may not apply broadly. The treatment involves strong chemotherapy and carries risks like infection and organ damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California at Los Angeles (UCLA )
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may one day personalize drug dosing after stem cell transplants
- New imaging agent aims to sharpen cancer detection
- Could a daily pill tame rare cancers in teens? new trial investigates
- Could your genes hold the key to cancer risk? scientists investigate families
- Cancer patients get help planning families in new study
- New hope for kids with resistant cancers: targeted drug enters trial